- Home
- ME vs ELEV Comparison
ME vs ELEV Comparison
Compare ME & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- ELEV
- Stock Information
- Founded
- ME 2006
- ELEV 2019
- Country
- ME United States
- ELEV United States
- Employees
- ME N/A
- ELEV N/A
- Industry
- ME Precision Instruments
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- ELEV Health Care
- Exchange
- ME Nasdaq
- ELEV Nasdaq
- Market Cap
- ME 40.0M
- ELEV 37.6M
- IPO Year
- ME N/A
- ELEV 2021
- Fundamental
- Price
- ME $1.82
- ELEV $0.50
- Analyst Decision
- ME Hold
- ELEV Buy
- Analyst Count
- ME 1
- ELEV 6
- Target Price
- ME $9.40
- ELEV $7.20
- AVG Volume (30 Days)
- ME 466.4K
- ELEV 1.0M
- Earning Date
- ME 01-28-2025
- ELEV 03-06-2025
- Dividend Yield
- ME N/A
- ELEV N/A
- EPS Growth
- ME N/A
- ELEV N/A
- EPS
- ME N/A
- ELEV N/A
- Revenue
- ME $208,775,000.00
- ELEV N/A
- Revenue This Year
- ME $22.00
- ELEV N/A
- Revenue Next Year
- ME $17.31
- ELEV N/A
- P/E Ratio
- ME N/A
- ELEV N/A
- Revenue Growth
- ME N/A
- ELEV N/A
- 52 Week Low
- ME $1.34
- ELEV $0.42
- 52 Week High
- ME $12.76
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- ME 37.81
- ELEV 39.41
- Support Level
- ME $1.48
- ELEV $0.46
- Resistance Level
- ME $1.75
- ELEV $0.53
- Average True Range (ATR)
- ME 0.17
- ELEV 0.05
- MACD
- ME 0.02
- ELEV -0.00
- Stochastic Oscillator
- ME 40.43
- ELEV 36.30
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.